Login to Your Account

Antisoma Shares Take a Tumble After Late-Stage NSCLC Failure

By Nuala Moran

Tuesday, March 30, 2010
LONDON - Shares in Antisoma plc plummeted 66 percent on news that its partner Novartis AG was stopping the Phase III trial of its lead product ASA404 in non-small-cell lung cancer (NSCLC), after an interim analysis showed the 1,200-patient study was futile. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription